Search

Article Information


Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology
Birkinshaw, Julian , Ivanka Visnjic, and Simon Best
60/4  (Summer 2018): 74-100

How do incumbent firms respond over time to a potentially disruptive technology? This article documents the strategies of 12 large pharmaceutical firms over 25 years as they addressed the opportunity/threat of biotechnology. All showed awareness of biotechnology’s potential, but their response profiles varied dramatically in terms of timing (early/late) and focus (external/internal). Late movers mostly made large acquisitions to "catch up," but early movers maintained their lead in terms of biotechnology-based drug sales and profitability, and those with a more "open" response profile performed better. This response involves a three-step process: building awareness (sensing), building capability (responding), and building commitment (scaling).

 

California Management Review

Berkeley-Haas's Premier Management Journal

Published at the University of California for more than sixty years, California Management Review seeks to share knowledge that challenges convention and shows a better way of doing business.

Learn more
Follow Us